Abstract

The distribution of muscle weakness in myasthenia gravis (MG) patients with acetylcholine receptor (AChR) antibodies is highly variable. As muscle groups respond differently to therapeutic interventions, it is important to acknowledge this variability. We analysed the distribution of muscle weakness in 225 AChR MG patients over time. On the basis of combinations of muscle weakness, seven phenotypes were defined: ‘ocular’ (O), ‘bulbar’ (B), ‘neck/limbs/respiratory’ (NLR), or a combination (O+B, O+NLR, B+NLR and O+B+NLR). MG remained restricted to ocular weakness in 5%, whereas 7% never had ocular weakness. At last follow-up, ocular or bulbar weakness had resolved more frequently than NLR weakness (40%, 38% and 25%; p = 0.003, respectively). Patients with O, B or OB phenotype at baseline had a higher age at onset and were more frequently male than patients with NLR, ONLR, BNLR or OBNLR phenotype (52.7 ± 17.5 vs. 44.0 ± 18.9; p = 0.007 and 64% vs. 37%; p = 0.002, respectively). MG patients have heterogeneous distributions of muscle weakness and frequently shift between phenotypes. The phenotypic variations found in AChR MG suggest that also other factors aside from the AChR antibody mediated immune response are of importance in determining the disease expression in MG.

Highlights

  • Myasthenia gravis (MG) is an autoimmune disease, mediated by antibodies to a number of well characterized autoantigens. [1] current knowledge on the involved autoantigens does not provide conclusive answers for the large heterogeneity that is observed in distribution of muscle weakness and the shifts in this distribution within individual MG patients

  • Treatment choices and clinical trials as some studies show that ocular or generalized weakness responds distinctly to different therapies. [3,4,5] the sensitivity of outcome scales for changes in muscle weakness depends on the muscles involved. [6,7] In this study, we systematically analysed the distribution of muscle weakness in acetylcholine receptor (AChR) MG patients and shifts in this distribution within patients

  • In a cohort of 225 AChR MG patients, we found a high heterogeneity in the distribution of muscle weakness and a frequent occurrence of shifts between phenotypes in individual patients

Read more

Summary

Introduction

Myasthenia gravis (MG) is an autoimmune disease, mediated by antibodies to a number of well characterized autoantigens. [1] current knowledge on the involved autoantigens does not provide conclusive answers for the large heterogeneity that is observed in distribution of muscle weakness and the shifts in this distribution within individual MG patients. [1] current knowledge on the involved autoantigens does not provide conclusive answers for the large heterogeneity that is observed in distribution of muscle weakness and the shifts in this distribution within individual MG patients. The most frequently involved autoantigen is the acetylcholine receptor (AChR), against which antibodies are present in about 85% of MG patients. [2] the exposure of the target antigens to circulating serum antibodies should be similar for all muscles, different patterns of muscle weakness are observed in individual patients. [3,4,5] the sensitivity of outcome scales for changes in muscle weakness depends on the muscles involved. [6,7] In this study, we systematically analysed the distribution of muscle weakness in AChR MG patients and shifts in this distribution within patients Acknowledging different phenotypes in MG might be of importance in treatment choices and clinical trials as some studies show that ocular or generalized weakness responds distinctly to different therapies. [3,4,5] the sensitivity of outcome scales for changes in muscle weakness depends on the muscles involved. [6,7] In this study, we systematically analysed the distribution of muscle weakness in AChR MG patients and shifts in this distribution within patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call